Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

The Chinese University of Hong Kong

Status and phase: Begins enrollment in 2 months; Phase 2

Conditions: Lung Cancer (NSCLC)

Treatments: Drug: Osimertinib alone; Radiation: Local ablative therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT07379476

LUNXXX

Details and patient eligibility

About

This is an open-label, multicentre, randomized phase II clinical trial. Patients with stage IV (AJCC 9th edition) non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or exon 21 L858R mutation, who had less than or equal to 3 active oligoresidual cancer sites amenable to local ablative therapy (LAT) (as determined by physician) after 3-6 months of firstline osimertinib treatment, are eligible. Subjects will be randomized 1:1 to osimertinib with or without LAT.

Enrollment: 64 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years of age or older and able to understand and give written informed consent
• Pathologically proven non-small cell lung cancer
• Positive for EGFR exon 19 deletion or EGFR exon 21 L858R mutation (either by tissue or plasma testing)
• Stage IV disease
• Receive first line osimertinib monotherapy for stage IV disease
• Undergo a PET-CT scan after 12-24 weeks of initiation of osimertinib treatment, with no evidence of disease progression, and less than or equal to 3 active disease sites (including primary tumour) amenable to local ablative therapy, as determined by investigator
• At least one brain imaging (CT Brain or MRI Brain with contrast, preferably MRI Brain), either at time of diagnosis or while on osimertinib treatment but before randomization, to document CNS status for stratification. Patients with asymptomatic CNS metastases are eligible. For patients with brain metastases diagnosed at baseline, follow up brain imaging is recommended before randomization.
• Patients with history of palliative radiotherapy are eligible
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Adequate haematological values: haemoglobin ≥9.0g/dL, absolute neutreophil count ≥1.0 x 109/L, platelet count ≥100 x 109/L
• Adequate hepatic function: bilirubin ≤1.5 x ULN, AST/ALT ≤2.5 x ULN
• Adequate renal function: creatinine clearance ≥30ml/min, according to the formula of Cockcroft-Gault equation
• Willing and able to comply with the requirements and restrictions in this protocol

Exclusion criteria

• Previous or concomitant malignancy within 5 years prior registration with the exception of adequately treated localized non-melanoma skin cancer or cervical cancer in situ.
• Mixed SCLC and NSCLC histology
• Positive pregnancy test
• Contraindication to radiotherapy
• Any serious underlying medical, psychiatric, psychological, familial condition that in the judgement of the investigator, that may interfere with planned staging, treatment and follow up, affect patient compliance, or place the patient at high risk from treatment related complications

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

64 participants in 2 patient groups

Radiotherapy arm

Experimental group

Description:

* Continue osimertinib as per standard of care (40mg or 80mg daily). * Undergo radiotherapy to 1-3 disease sites as determined by the investigator.

Treatment:

Radiation: Local ablative therapy

Control arm

Active Comparator group

Description:

Continue osimertinib as per standard of care (40mg or 80mg daily)

Treatment:

Drug: Osimertinib alone